Under a high-dose (5 μM) verteporfin treatment, the production of IL-17A, IL-6, IL-10, TNF-α, and IFN-γ was significantly inhibited in T cells of both healthy controls and patients with SLE (Fig. 5B). Here, IL17A is linked to systemic lupus erythematosus.